Deciphera Pharmaceuticals Inc. (NASDAQ: NASDAQ:DCPH ) has experienced a meteoric rise in its stock price following the announcement of its acquisition by Ono Pharmaceutical for $2.4 billion. This strategic move has not only boosted investor confidence but also solidified Ono's position in the oncology space. However, with Deciphera's stock ( NASDAQ:DCPH ) trading...
it looks like this is taking off for a continuation of gap up until former monthly consolidation level is reached.
i like this long until it breaks trend.
NASDAQ:DCPH - waiting for the fast correction to the level 0f 13, after that it has a chance to turn around and start moving to 21. Horizon of the probable profit seems near the year.
Does not constitute a recommendation.
#furoreggs #investing #stocks #shares #idea #forecast #trading #analysis
If you want to discuss, please subscribe and challenge this point of view
Introduction
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) is at the forefront of developing innovative cancer treatments, with a keen focus on leveraging their proprietary switch-control kinase inhibitor platform. The company has made significant strides, particularly with its flagship product, QINLOCK, and the promising pipeline candidate vimseltinib, aiming...
RSI is on the rise. Many bulls showed up with the earnings call plus it looks like a inverse head and shoulders is forming. MACD is reversing for the bulls and the volume is 958K. this position is above the 200 moving day average which is a sign of trend changes. The white lines are the next levels this could reach. Stop loss is at the 200 MA.
Price is working its way to the end of the wedge and closed above the 1.61 fib level after pulling back from a bull flag. OBV crossed its 20 day EMA, D+ crossed D- on the ADX and the MACD is curling up lookin like it will cross over soon.
target: 18.31
LONG-TERM: 4hr classic bullish divergence, Daily MACD quadruple classic bullish divergence and RSI divergence, Bullish cypher harmonic pattern (not perfect), and over a critical support. The white line is a place to take some profits but $64.69 is the real long term target (not financial advice)
Why get subbed to to me on Tradingview?
-TOP author on TradingView
-15+ years experience in markets
-Professional chart break downs
-Supply/Demand Zones
-TD9 counts / combo review
-Key S/R levels
-No junk on my charts
-Frequent updates
-Covering FX/crypto/US stocks
-24/7 uptime so constant updates
DCPH 2D:: Best level to BUY // 150%+ SWING trade...
Clinical-stage biotech company so be careful. But nice ascending triangle to trade. Need to see a close above $70 or a high volume pop to enter long. Would like to see one more low volume, shallow pullback before the break.
Deciphera Pharmaceuticals (DCPH) is forming a triangle after a big run-up.
This is not a trade yet. Ideally, I want to see the stock consolidate near the top of the triangle. Otherwise, I want to see a strong move out of the triangle on a one-day move with the price closing near its daily highs and well outside the pattern. I am looking for an initial target near...
Pure technical trade based on R/R and nothing else
Today appears favoring bulls,
hopefully everyone who wanted out gots flushed out on that waterfall.
RSI and CCI in uptrend and confirming so far.
Setting alert for price to close above 5 ema, needs at least one more day of consolidation for proof.
Once PA finds support after INSIDERS, sell some of their initial shares for a profit from $17.00, then it will be time to go long again. Patience Is Key!!
IPO Lockup Expiration will be on 3/27/2028 (Tuesday) and TREND is bearish, stay on it until PA proves it has found a SUPPORT level.
WALTHAM, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the closing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds from the...
